An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson's disease and restless legs syndrome

Drugs
Jan-Peer ElshoffMarina Braun

Abstract

This narrative review reports on the pharmacological and pharmacokinetic properties of rotigotine, a non-ergolinic D₃/D₂/D₁ dopamine receptor agonist approved for the treatment of early- and advanced-stage Parkinson's disease (PD) and moderate to severe restless legs syndrome (RLS). Rotigotine is formulated as a transdermal patch providing continuous drug delivery over 24 h, with a plasma concentration profile similar to that of administration via continuous intravenous infusion. Absolute bioavailability after 24 h transdermal delivery is 37 % of the applied rotigotine dose. Following a single administration of rotigotine transdermal system (24-h patch-on period), most of the absorbed drug is eliminated in urine and feces as sulphated and glucuronidated conjugates within 24 h of patch removal. The drug shows a high apparent volume of distribution (>2500 L) and a total body clearance of 300-600 L/h. Rotigotine transdermal system provides dose-proportional pharmacokinetics up to supratherapeutic dose rates of 24 mg/24 h, with steady-state plasma drug concentrations attained within 1-2 days of daily dosing. The pharmacokinetics of rotigotine transdermal patch are similar in healthy subjects, patients with early- or advanced-stage ...Continue Reading

References

Jan 1, 1986·Clinical Neuropharmacology·J D Parkes
May 20, 1999·The Annals of Pharmacotherapy·J A Barone
Aug 17, 2000·Journal of Neurology, Neurosurgery, and Psychiatry·A SchragN Quinn
Jun 5, 2003·American Journal of Epidemiology·Stephen K Van Den EedenLorene M Nelson
Nov 1, 2003·Sleep Medicine·R P AllenC J Earley
Jan 28, 2004·Archives of Internal Medicine·Klaus BergerChristof Kessler
Apr 18, 2007·Neurology·Peter A LeWittUNKNOWN SP 650 Study Group
May 16, 2007·Archives of Neurology·Joseph JankovicBabak Boroojerdi
Sep 1, 2007·BMJ : British Medical Journal·C E Clarke
Oct 16, 2007·Movement Disorders : Official Journal of the Movement Disorder Society·Nir GiladiUNKNOWN SP513 investigators
Feb 15, 2008·Expert Review of Neurotherapeutics·Lorraine O RamigShimon Sapir
Mar 18, 2008·Journal of Neurology, Neurosurgery, and Psychiatry·J Jankovic
Jul 25, 2008·Clinical Pharmacology and Therapeutics·M MalikM Braun
Aug 16, 2008·Naunyn-Schmiedeberg's Archives of Pharmacology·Dieter SchellerHermann Lübbert
Dec 20, 2008·British Journal of Clinical Pharmacology·Marina BraunRolf Horstmann
Jul 18, 2009·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Willi CawelloHilmar Boekens
Jul 25, 2009·Journal of Clinical Pharmacology·Marina BraunRolf Horstmann
Sep 11, 2009·British Journal of Clinical Pharmacology·Marina BraunRolf Horstmann
Jun 10, 2010·Nature Reviews. Neurology·Claudia Trenkwalder, Walter Paulus
Jul 16, 2010·Movement Disorders : Official Journal of the Movement Disorder Society·Wayne A HeningUNKNOWN SP792 Study Group
Nov 26, 2010·Journal of Neurology·E HametnerW Poewe
Feb 9, 2011·Parkinsonism & Related Disorders·Claire HinnellMichael Samuel
Feb 16, 2011·Movement Disorders : Official Journal of the Movement Disorder Society·Claudia TrenkwalderUNKNOWN Recover Study Group
Jun 1, 2011·Movement Disorders : Official Journal of the Movement Disorder Society·Olivier RascolWerner Poewe
Jun 29, 2011·British Journal of Clinical Pharmacology·Willi CawelloMarina Braun
Oct 1, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Yoland SmithMahlon R DeLong
Oct 28, 2011·Parkinsonism & Related Disorders·S R SchreglmannC R Baumann
Dec 14, 2011·The Neurologist·Maria Cruz Rodriguez-OrozOriol de Fabregues

❮ Previous
Next ❯

Citations

Jul 18, 2016·Journal of the Neurological Sciences·Alberto RomagnoloMario Giorgio Rizzone
May 26, 2016·Expert Opinion on Drug Metabolism & Toxicology·Luigi Ferini-StrambiAndrea Galbiati
Jul 19, 2016·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·A AntoniniD Weintraub
Feb 23, 2017·Neurological Research·Siegfried MuhlackThomas Müller
Jan 15, 2018·European Journal of Drug Metabolism and Pharmacokinetics·Willi CawelloJens-Otto Andreas
Jun 2, 2017·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Yuichi Sugiyama
Sep 2, 2020·Expert Opinion on Drug Safety·Fabrizio StocchiMargherita Torti
Aug 20, 2019·Expert Opinion on Pharmacotherapy·Stefano de BiaseMariarosaria Valente
Apr 11, 2019·Drugs·Margherita TortiFabrizio Stocchi
Mar 17, 2020·Current Pharmaceutical Design·Shadab MdNabil A Alhakamy
Jan 5, 2017·Parkinson's Disease·Mariana BabayevaZvi Loewy
Mar 1, 2019·Scientific Reports·Christian HausmannMonika Schäfer-Korting
Jun 28, 2019·CNS Drugs·James E Frampton
Dec 5, 2020·Journal of AOAC International·Thamara de Carvalho MendesValeria Pereira de Sousa
Jul 29, 2020·Neurología : publicación oficial de la Sociedad Española de Neurología·R García-RamosJ C Martínez Castrillo
Feb 1, 2020·Current Pharmaceutical Design·Bhumika KumarP K Sahoo
Jul 6, 2021·Aging and Disease·Dipali NemadeVikram Shivkumar
Jul 6, 2021·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Jie BaiShuang Hu

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.